Sara Barbat

Statistics

Publications

Citations

H-Index

Active since

2020

Affiliations

Amplyx Pharmaceuticals (United States)(Current)

Tel Aviv University

Institut Jules Bordet

CHU Dinant Godinne UCL Namur

Tel Aviv Sourasky Medical Center

Sara Barbat is an author at Amplyx Pharmaceuticals (United States) specializing in antifungal agents, antifungal pharmacotherapy, and antifungal therapy.

Publications per year

2020–2023

Publications

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

Peter G. Pappas, José A. Vázquez, Ilana Oren et al. · Journal of Antimicrobial Chemotherapy · 2023 · 59 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

Peter G. Pappas, Bart Jan Kullberg, José A. Vázquez et al. · Open Forum Infectious Diseases · 2020 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia

Oliver A. Cornely, Helmut Ostermann, Philipp Koehler et al. · Journal of Antimicrobial Chemotherapy · 2023 · 17 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

1–3 of 3